ENTA enanta.com: Price-to-Projected Revenue Ratio

Public company logo of Enanta Pharmaceuticals Inc. (ENTA)

Effective management at Enanta Pharmaceuticals (ENTA) ensures R&D transparency and strict cost control. The prospects for new antiviral combinations are only beginning to emerge, as confirmed by the forward price-to-sales valuation, where the metric value is 4.90. However, low cash flow predictability due to irregular royalties makes cash generation unstable, creating risks for the long-term sustainability of the business.

Enanta Pharmaceuticals, Inc. - ENTA Forward P/S Multiple (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for Enanta Pharmaceuticals (ENTA)

- current price and projected stock value:
Stock Price enanta.com|ENTA - Average Forecast Price
- company stock capitalization data:
Market Value Enanta|ENTA - Business Value
- book value of equity indicators:
Book Value per Share Enanta Pharmaceuticals|ENTA - Book Capitalization|Market Value to Book Value Ratio enanta.com|ENTA - Total Business Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Enanta Pharmaceuticals|ENTA - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital enanta.com|ENTA - Company Aggregate Debts|Debt to Book Value Enanta Pharmaceuticals Inc.|ENTA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Enanta Pharmaceuticals|Quick Ratio enanta.com
- financial results and valuation multiples details:
ENTA - Final Profit|Projected Future Earnings Enanta Pharmaceuticals|ENTA - P/E Multiple|Future Price to Earnings Enanta Pharmaceuticals|ENTA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Enanta Pharmaceuticals Inc.|ENTA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Enanta Pharmaceuticals|ENTA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth enanta.com|ENTA - Net earnings per share growth this year|Earnings growth forecast for next year Enanta Pharmaceuticals
- total revenue and sales volume data:
ENTA - Company Total Revenue|Company Future Sales Volume Enanta Pharmaceuticals Inc.|ENTA - P/S Multiple|Forward Price-to-Revenue Multiple Enanta Pharmaceuticals, Inc|ENTA - Revenue Change YoY (Last 12 Months)
Fundamental company analysis:Enanta (ENTA)
Manufactured products of Enanta Pharmaceuticals, Inc

The forward P/S dynamics of Enanta Pharmaceuticals (ENTA) allow for a correlation between the company's market value and expected sales volume, considering the business support provided by royalties during the development of new antiviral agents. This indicator is calculated as the ratio of market capitalization to projected revenue, determining the degree of overpayment for the asset and helping investors identify optimal entry points based on consensus estimates.

Key competitors

Forward P/S Multiple GILD (Gilead)|CDTX - Forward Price-to-Revenue Multiple|NVAX - Price-to-Projected Revenue Ratio|CVAC - Forward P/S Multiple|Valneva (VALN) - Price-to-Projected Revenue Ratio|Vir Biotechnology - Forward Price to Sales|SIGA (SIGA Technologies Inc) - Forward P/S Multiple|EBS - Projected Price to Revenue|Forward Price-to-Revenue Multiple AVIR (Atea Pharmaceuticals)|Price-to-Projected Revenue Ratio IVVD (Invivyd Corp)|Inovio - Forward Price-to-Revenue Multiple|HilleVax - Price-to-Projected Revenue Ratio|KLRS - Price-to-Projected Revenue Ratio|Forward Price to Sales DYAI (dyadic.com)|NNVC: Forward P/S Multiple|Talphera (TLPH) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cocrystal Pharma|Forward P/S Multiple trawspharma.com|Forward P/S Multiple DWTX|Price to Expected Revenue Ratio QLGN|Forward P/S Multiple ALVR (AlloVir, Inc.)|VBI Vaccines Inc. (VBIV) - Market Cap to Future Revenue Ratio|Virios Therapeutics - Forward P/S Multiple|VXRT: Price-to-Projected Revenue Ratio